A pioneer in the field of probiotic solutions, Vésale Pharma is a Walloon company that has been marketing probiotic specialties for more than 15 years based on the latest scientific discoveries. Vésale Pharma markets a very wide range of products targeting the digestive sphere, the pediatric sphere and women’s health. Its products are currently marketed in Europe, Asia and the Middle East via a network of distributors and in Belux via pharmacies. Vésale Pharma places innovation at the heart of its activities and devotes 23% of its turnover to R&D activities with an internal staff of 7 people. Vésale collaborates with research centers in Belgium and abroad.
Vésale Pharma is born
In 2012, Vésale Pharma patented a micro-encapsulation process for probiotics (Intelicaps®) which protects probiotics from humidity and heat. The process also protects bacteria from gastric acid and pancreatic juice without altering their functionality.
In June 2016, Vésale Pharma inaugurated a new production unit coupled with its R&D activities in Ghlin.
Creation of Vésale Bioscience, a spin-out from Vésale Pharma dedicated to phagotherapy
In 2022, Vésale Pharma will continues its research activities along 3 ranges (Women Health, Digestive and Pediatric) to bring new products to market from 2022.
Vésale Pharma therefore relies on the development of innovative products to remain competitive. The products marketed by Vésale Pharma have the following characteristics:
Unlike large probiotic solution providers Vésale has the flexibility (“agility”) to quickly adapt the composition and galenic of its products (capsules, sachets, oro-soluble powder, tablets, tablets, chewable tablets or form liquid in order to allow their administration to each member of the family (including the pregnant woman).